Global Prostate Health Market Trends and Growth Forecast by 2032
The Prostate Health Market is predicted to advance vigorously. It is poised to attain a CAGR of 9% during the forecast period 2022-2032, according to the prostate health market report by Future Market Insights (FMI).
Grants for BPH treatment research and the fact that obesity
causes several mechanisms, including increased sympathetic nervous activity,
increased inflammation process, and oxidative stress, all of which are
conducive to the development of BPH, are likely to accelerate prostate
health market growth.
Cancer patients are at higher risk of COVID-19 infection
than adults with good prostate health, according to major
regulatory bodies around the world (such as the WHO, MHRA, TGA, and EMA) and
screening, diagnostic exams, and surgical procedures in hospitals and cancer
centres are severely limited or postponed.
As a result, caregivers and hospitals can expect delays in
elective surgeries and screening procedures.
However, since the second half of 2020, the market has
gradually increased due to an increase in the number of oncology appointments
and rise in adoption of prostate health therapies, among other
things, as a result of efforts to clear backlogs and new cases, which further
shapes the prostate health market future trends.
Other factors that contribute to the demand for
prostate health treatment include an increase in demand for prostate
cancer treatment and management and an increase in the use of hormonal
agents in non-metastatic castration-resistant (nmCRPC) and metastatic hormone
nave (mHNPC) prostate cancer settings.
Moreover, the developing economies’ untapped potential
presents lucrative prostate health market opportunities during
the forecast period.
Prolonged treatment times and low demand for prostate
cancer medical treatment drugs in developing countries, on the other
hand, are expected to shrink the prostate health market size.
Though both drugs and surgery can treat BPH and improve
prostate health, they have significant side effects. Dizziness, orthostatic
hypotension, and rhinitis are common alpha-blocker side effects.
These are of particular concern in the elderly, as they can
result in significant morbidities such as falls, and subsequent injuries are
expected to impact the prostate cancer treatment adoption trends.
As per the prostate health market study, the
market is forecasted to garner a worth of about US$ 50 Bn by 2026.
Key Takeaways:
- Due
to significant growth in the geriatric population and a large target
patient population, prostate cancer is expected to
account for the largest share of the prostate health market based on
disease indication.
- Neurostimulation
devices are anticipated to have the highest prostate health market
share in the type market.
- Attributing
to the strong presence of hospital pharmacies around the world and the
convenience offered by hospital pharmacies, the hospital pharmacies
segment is projected to lead the prostate cancer treatment market.
- The
crucial factor for Asia-Pacific’s market growth can be credited to the
rapidly growing patient population for benign prostatic hyperplasia in the
region, particularly in Japan, China, South Korea, Hong Kong, and Taiwan.
“USFDA took steps to boost the growth of the cancer therapy
market by approving drugs that are still in the clinical stage, thereby
speeding up clinical trials and investments in R&D by businesses and
research organizations can be credited to market growth in the United States
which is a major contributor to the North American prostate health market.
Moreover, favourable reimbursement policies, a strong
healthcare infrastructure, and some other emerging trends in the prostate
health market such as product launches have also contributed to the
market’s rapid growth.” asserts an FMI analyst.
Competitive Landscape:
AstraZeneca plc, Bristol-Myers Squibb Company, Astellas
Pharma Inc., F. Hoffmann-La Roche AG, Bayer AG, erring Pharmaceuticals Inc., Ferring
Pharmaceuticals Inc., Ipsen Pharma, Johnson & Johnson, Takeda
Pharmaceutical Company Ltd. and GlaxoSmithKline Plc are among the key players
in the prostate health market.
Within the global prostate cancer diagnostic market,
there are several significant drug and equipment manufacturers, and their
status as a significant players is primarily based on specific product markets.
Players have been looking for novel ways to expand their
market through innovative prostate product launches.
Recent developments in the prostate health
market are as follows:
- The
first commercial production of Axumin (fluciclovine) in Italy was
announced by Blue Earth Diagnostics, with the first Italian patients being
dosed.
- Myovant
partnered with Pfizer to commercialize Orgovyx (relugolix), a prostate
cancer drug.
- In the United States, Dr Reddy
introduced generic Abiraterone Acetate Tablets USP, 250 mg, which is a
therapeutic equivalent generic version of Zytiga (abiraterone acetate) for
prostate cancer.
Browse More@ https://www.futuremarketinsights.com/reports/prostate-health-market
Comments
Post a Comment